2021 - 2022

Wellcome Trust

Assessment of the Factors Enabling the Rapid Development and Authorisation of COVID-19 Vaccines

MMGH conducted an assessment on behalf of the Wellcome Trust to understand the impact of different factors which enabled the rapid clinical development and regulatory authorisation for COVID-19 vaccines. The project approach is comprised of extensive stakeholder surveys and interviews complemented by a literature review, quantitative analyses, including a regression analysis, and expert focus groups. Together, these activities identified the key factors that influenced the clinical development timelines for COVID-19 vaccines and highlighted which factors could be replicated in future vaccine development efforts.

Related Publication(s)


Covid-19 vaccines: the factors that enabled unprecedented timelines for clinical development and regulatory authorisation...


Historically, clinical development and approval of vaccines have spanned approximately 10 years with only ~16% of vaccine candidates ever receiving market authorisation. The long timelines and the low success rates are the product of the complex ecosystem where each vaccine...